Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
Emotions
Interventions
DRUG

Lamotrigine

Orally; 300 mg

DRUG

Ketamine

Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min

DRUG

Placebo Pretreatment

Lamotrigine Placebo

DRUG

Placebo Infusion

Ketamine Placebo

Trial Locations (1)

12247

Medical School Berlin, Berlin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER

NCT04156035 - Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine | Biotech Hunter | Biotech Hunter